{"id":"W2702220459","doi":"10.1200/jco.2016.34.15_suppl.1014","title":"Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Internal medicine; Epirubicin; Fluorouracil; Hazard ratio; Breast cancer; Neoadjuvant therapy; Oncology; Bevacizumab; Gastroenterology; Chemotherapy; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002759429,0.0005013198,0.0007981448,0.0002345161,0.000194878,0.0006457225,0.0003740421,0.0008746706,0.002515669],"category_scores_gemma":[0.001605117,0.0002627028,0.001239943,0.0002542138,0.0005585699,0.0006248337,0.0003801269,0.001356315,0.0003167324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008459266,"about_ca_system_score_gemma":0.0004962708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005526319,"about_ca_topic_score_gemma":0.001373253,"domain_scores_codex":[0.9993138,0.0004035892,0.00004417611,0.00008937481,0.00005183852,0.00009713606],"domain_scores_gemma":[0.9991294,0.000322789,0.0002195286,0.00005957498,0.00003162188,0.0002372353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9556643,0.003611493,0.01363379,0.0002654721,0.0006324396,0.00007279842,0.00006698712,0.00104473,0.002694787,0.00007758239,0.0008175292,0.02141827],"study_design_scores_gemma":[0.2869831,0.5991689,0.1019032,0.0001239799,0.002453266,0.0003451091,0.0001023334,0.00190524,0.002828396,0.0004621197,0.003674998,0.00004925705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964006,0.00187277,0.0001201435,0.0001722844,0.00005745347,0.0001930191,0.0005648606,0.000007326107,0.0006114923],"genre_scores_gemma":[0.9958626,0.0007042444,0.0002313353,0.0001865715,0.0001018182,0.0003787113,0.001316866,0.000004156298,0.001213638],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002759429,"threshold_uncertainty_score":0.01459342,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04928208624831391,"score_gpt":0.4058657505085966,"score_spread":0.3565836642602827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}